Role of 5'-nucleotidase in Thiopurine Metabolism: Enzyme Kinetic Profile and Association with Thio-GMP Levels in Patients with Acute Lymphoblastic Leukemia During 6-mercaptopurine Treatment
Overview
Authors
Affiliations
Thiopurines are used for treatment of several diseases. Cytotoxicity is caused by the derived compounds 6-thioguanine nucleotides (TGNs) and methyl-6-thioinosine monophosphate (methylthio-IMP). The 6-thiopurine mononucleotides 6-thio-IMP (thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 5'-nucleotidase. It has been shown that the various 5'-nucleotidases are key enzymes for (6-thio)-purine metabolism. We aimed to investigate whether the overall 5'-nucleotidase (5'NT) activity is correlated with the efficacy and toxicity of 6-thiopurine nucleotides. Substrate affinity of 5'NT for IMP, GMP, AMP, thio-IMP, thio-GMP and methylthio-IMP was studied in human lymphocytes. For each of the substrates, the pH for optimal overall enzyme activity has been determined at a pH range between 6 and 10. At the optimal pH, assays were performed to establish Km and Vmax values. Optimal pH values for the various substrates were between 7 and 8.5. Km values ranged from 33 to 109 microM, Vmax ranged from 3.99 to 19.5 nmol/10(6) peripheral mononuclear cells (pMNC) h, and Vmax/Km ratios ranged from 105 to 250. The results did not show a distinct preference of 5'NT activity for any of the tested thiopurine nucleotides. The enzyme kinetic studies furthermore revealed substrate inhibition by thio-IMP and thio-GMP as a substrate. Inhibition by thio-GMP also seems to occur in patients treated with 6-mercaptopurine (6 MP); subsequently, this may lead to toxicity in these patients.
Jin Q, Gutierrez Diaz B, Pieters T, Zhou Y, Narang S, Fijalkwoski I Sci Adv. 2022; 8(49):eabq8437.
PMID: 36490346 PMC: 9733937. DOI: 10.1126/sciadv.abq8437.
Guo H, Zhao Y, Wang W, Dong N, Hu Y, Zhang Y Front Pharmacol. 2022; 13:941182.
PMID: 36238550 PMC: 9552076. DOI: 10.3389/fphar.2022.941182.
Reglero C, Dieck C, Zask A, Forouhar F, Laurent A, Lin W Cancer Discov. 2022; 12(11):2646-2665.
PMID: 35984649 PMC: 9633388. DOI: 10.1158/2159-8290.CD-22-0010.
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.
Follini E, Marchesini M, Roti G Int J Mol Sci. 2019; 20(12).
PMID: 31226848 PMC: 6627878. DOI: 10.3390/ijms20123021.
Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Dieck C, Ferrando A Blood. 2019; 133(21):2263-2268.
PMID: 30910786 PMC: 6533602. DOI: 10.1182/blood-2019-01-852392.